H1N1 vaccine linked to narcolepsy in Finland

[Eldritch]

http://yle.fi/ecepic/archive/00342/sikainfluenssarokot_342156b.jpg

Finland's National Institute for Health and Welfare (THL) has recommended that vaccination against the H1N1 swine flu virus with the Pandemrix vaccine be suspended. The vaccine is not to be used until it is determined if it is linked to an increase in the number of cases of narcolepsy in the country.

THL says that the recommendation is a precautionary measure. At the moment there is no swine flu epidemic in the country that would require urgent vaccination against the virus.

"Indications of a time link between vaccinations and narcolepsy cases have been seen, but an actual link has not been established. In light of international information, a connection would even seem unlikely", Dr Hanna Nohynek, a special researcher at THL told YLE on Tuesday,

Exceptions can be made to the THL recommendation if needed. The vaccine can be given to people travelling to any area experiencing a swine flu epidemic.

Experts to gather

If required, a final decision on a nationwide end to the swine flu vaccination programme will be made by the Ministry of Social Affairs and Health. Such a decision will be taken if the reported cases of narcolepsy are proven to have resulted from the vaccine.

The group coordinating the investigation into the cases is scheduled to meet next Tuesday to make an overall evaluation. It is comprised of experts from THL, the Ministry of Social Affairs and Health, the National Agency for Medicines, The National Supervisory Authority for Welfare and Health Valvira, and representatives of provincial authorities.

According to the National Institute for Health and Welfare, the increase in the number of cases of narcolepsy may have been caused by the flu virus, by the vaccine, by the interaction of an infection with the vaccine, or some other factor. It is known that infections can cause narcolepsy.

THL has been notified of 15 cases of narcolepsy, six of which are more clearly associated with the vaccination than are the remainder. Preliminary research into the connection between the vaccine and the cases is expected to take several months. Annually up to 50 cases of narcolepsy are diagnosed in adults in Finland and fewer than 10 in children.

Worldwide, at least 90 million people have received the Pandemrix vaccine in more than 20 countries. However, so far a link to narcolepsy has been suspected only in Finland.

Link. (http://yle.fi/uutiset/news/2010/08/thl_recommends_suspension_of_h1n1_vaccinations_192 6808.html)

[Loki]

Here (http://xyrem.com/) is a good treatment for narcolepsy, the Finnish doctors can dish it out. :thumb001:

[The Ripper]

Now the vaccine-deals are being investigated for corruption. It always did seem very suspicious, the whole thing. I bet there is a lot of dirt to be found if only you went digging...

[Eldritch]

Now the vaccine-deals are being investigated for corruption. It always did seem very suspicious, the whole thing. I bet there is a lot of dirt to be found if only you went digging...

Don't be ridiculous, we're the least corrupted country in the world! Nothing like that could possibly happen here!

So says Pekka "Big Pharma's Bitch" Puska. :rolleyes:

[The Ripper]

Don't be rediculous, we're the least corrupted country in the world! Nothing like that could possibly happen here!

So says Pekka "Big Pharma's Bitch" Puska. :rolleyes:

Most of the corruption is institutionalized and state-mandated anyway, the rest is simply "Finnish custom"... ;)

[The Lawspeaker]

THL stops swine flu vaccinations (http://www.helsinkitimes.org/htimes/domestic-news/general/12224-thl-stops-swine-flu-vaccinations-.html)


The Finnish National Institute for Health and Welfare (THL) on Tuesday recommended that the use of the Pandemrix vaccine is suspended. The recommendation is a precautionary measure.

A possible connection between the swine flu vaccine and narcolepsy is currently being investigated. The THL has stopped the use of Pandemrix until the narcolepsy cases have been studied thoroughly.

Over the past year, neurologists in both Finland and Sweden have noted an increase in child narcolepsy cases, and suspect that this could be a harmful side effect of the swine flu vaccine.

In total, around 2.5 million Finns have received the Pandemrix vaccine, according to THL. Medical reports suggest that over 750 of those who have been vaccinated have experienced harmful effects.

[Eldritch]

Increased risk of narcolepsy observed among children and adolescents vaccinated with PandemrixR

1 Feb 2011

Among those 4-19 years of age who received Pandemrix®-vaccine had a manifold increased risk of falling ill with narcolepsy during the 8 months following vaccination in comparison to those unvaccinated in the same age group. Based on the evaluation done so far, the National Narcolepsy Task Force finds it probable that Pandemrix®-vaccination contributed to the observed increase in incidence of narcolepsy among those 4 -19 years of age. Currently, the most likely explanation is that the increase in narcolepsy is by joint effect of the vaccine and some other factor(s). At the moment, there is no evidence that the increase in narcolepsy observed in Finland could be attributed to the vaccine lots used. The results can be read in the Interim Report of the Task Force which is published on February 1st, 2011.

The association of Pandemrix-vaccination and narcolepsy was studied using extensive registry based data. Data gathered from hospital discharge registries on patients fallen ill with narcolepsy during years 2009-10 was linked with data from primary care records on pandemic vaccination. The observed association is so evident that it is unlikely that other so-called confounding factors could fully explain the phenomenon.

In Finland during years 2009–10, 60 children and adolescents aged 4-19 years fell ill with narcolepsy. These figures base on data from hospitals and primary care, and the review of individual patient records by a panel of neurologists and sleep researchers. Of those fallen ill, 52 (almost 90 percent) had received Pandemrix® vaccine, while the vaccine coverage in the entire age group was 70 percent. Based on the preliminary analyses, the risk of falling ill with narcolepsy among those vaccinated in the 4-19 years age group was 9-fold in comparison to those unvaccinated in the same age group. This increase was most pronounced among those 5–15 years of age. No cases were observed among those under 4 years of age. Also, no increase in cases of narcolepsy or signs of vaccination impacting risk of falling ill with narcolepsy was observed among those above 19 years of age.
In addition to Finland, increase in cases of narcolepsy observed only in Sweden and Iceland

In 2009, among countries using similar pandemic vaccine as was used in Finland, an increase in cases of narcolepsy has been observed only in Finland, Sweden and Iceland. Contrary to the observations in Finland, narcolepsy has occurred in greater numbers than expected also among unvaccinated children and teenagers in Iceland.

The association between narcolepsy and PandemrixR vaccine requires more investigations

During the coming months, these preliminary register based results will be confirmed in Finland. In further investigations, special attention will be given to infections and other stimuli in close time association with the pandemic vaccination. The significance of the possible joint effects will be explored.

In addition, other significant co-factors contributing to the onset of narcolepsy will be evaluated in epidemiologic, immunologic and genetic studies planned. The main aim of the immunologic studies is to clarify, whether the immunological responses to the different components of the Pandemrix® vaccine and to the A(H1N1) virus among those children and teenagers with genetic disposition to narcolepsy and those fallen ill with narcolepsy differ from the immunological responses of other children and teenagers not belonging to these risk groups.

It is also of utmost importance to find out whether the association is observed also elsewhere than in Finland. At present, Finland is participating in the ECDC contracted, VAESO led narcolepsy background incidence and case control studies which are being conducted in 9 European Union countries by pharmacovigilance researchers from Public Health Institutes, Regulatory Agencies and Universities. These studies will evaluate the contribution of the pandemic vaccines and other risk factors in the onset of narcolepsy, and confirm whether increase in incidence in narcolepsy is seen in other countries. The outcomes of these studies will be reported during early summer 2011.

By January 24, 2011, 56 notifications of narcolepsy in association with Pandemrix® vaccination have been received by the National Vaccine Adverse Events Register maintained at the National Institute of Health and Welfare in Finland. Of these, 54 cases belonged to the age group of 4–19 years. Among most of the notified cases, the onset of symptoms of narcolepsy had started approximately two months following Pandemrix® vaccination.

The final report from the National Narcolepsy Task Force will be released by 31st August 2011.

Further information

Terhi Kilpi
Director of Department of Vaccines and Immune Protection, Chairman of the Task Force
National Institute of Health and Welfare, THL
tel +358 20 610 8678

Hanna Nohynek
Vaccine Safety Officer, Secretary of the Task Force
National Institute of Health and Welfare,THL
Tel +358 20 610 8246

Link. (http://www.thl.fi/en_US/web/en/pressrelease?id=24103)

Somebody's head better roll for this. :cussing

[The Ripper]

Somebody's head better roll for this. :cussing

This was my first thought. My second thought was that it probably won't happen. But here's to hoping.

[The Ripper]

Rokotteet valmisti brittiläinen GlaxoSmithKline Oy, joka rahoittaa tänä vuonna THL:n pneumokokki-rokotetutkimusta peräti kuudella miljoonalla eurolla. Kyse on valtavasta summasta, sillä valtiolta THL:n rokoteosasto saa noin miljoonan vuodessa.
¨

http://www.iltalehti.fi/sikainfluenssa/2009112110636139_si.shtml

Briefly in English: the vaccine came from a company that funds the research of THL (National Institute for Health and Welfare, government agency responsible for vaccine purchases) with 6 million euros, 6 times more than the funding from the Finnish state.

:rolleyes:

[Thorum]

This was my first thought. My second thought was that it probably won't happen. But here's to hoping.

No heads will roll because there is no evidence or proof the vaccine causes narcolepsy. Simple as that...

60 children out of 90 million vaccinations. Give me a break...

[Eldritch]

No heads will roll because there is no evidence or proof the vaccine causes narcolepsy. Simple as that...

60 children out of 90 million vaccinations. Give me a break...

Well, narcolepsy cases increased sevenfold among the children vaccinated (21 cases out of 10,000 as opposed to the statistical norm, 3/10,000), and Finland's National Institute for Health and Welfare (http://www.thl.fi/en_US/web/en) found no possible alternative causes for it, other than the Pandemrix vaccine.

Now, notice the exact nature of the findings: that there is no other explanation for increased prevalence of narcolepsy in Finland than the PandemrixR H1N1 vaccine.

The study did not find that all vaccinations are a ZOG conspiracy to lower birthrates all over the Western world, or some other such nonsense.

That the moronic (and already catastrophically harmful (http://www.city-journal.org/2011/bc0201td.html), even with their minor influence) anti-vaccination movement will use the findings to further their cause, is no excuse to pretend they aren't there.

[Thorum]

I believe, along with Autism, that it is finally being diagnosed properly and more often.

"Narcolepsy (http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm) is not rare, but it is an underrecognized and underdiagnosed condition. The disorder is estimated to affect about one in every 2,000 Americans. But the exact prevalence rate remains uncerntain, and the disorder may affect a larger segment of the population.
Narcolepsy appears throughout the world in every racial and ethnic group, affecting males and females equally. But prevalence rates vary among populations. Compared to the U.S. population, for example, the prevalence rate is substantially lower in Israel (about one per 500,000) and considerably higher in Japan (about one per 600)."